The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB),
including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB
correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system.
Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly
prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.
Formulary Announcements in new ARO System
-
wrote on 3 Sept 2022, 01:52 last edited by
In the new system, if we are creating an email to announce coverage (1 per province), with the only difference in content being the reimbursement criteria, would this be considered a "series" submission?
-
J Jennifer Carroll moved this topic from PAAB Code on 6 Sept 2022, 15:15
-
In the new system, if we are creating an email to announce coverage (1 per province), with the only difference in content being the reimbursement criteria, would this be considered a "series" submission?
wrote on 6 Sept 2022, 15:17 last edited byHello @gmc , hope you had a great long weekend.
A series submission would be acceptable for this type of APS if it meets the series submission requirements of 60% pick-up.